Journal ArticleDOI
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Olaf Penack,Monia Marchetti,Tapani Ruutu,Mahmoud Aljurf,Andrea Bacigalupo,Francesca Bonifazi,Fabio Ciceri,Jan J. Cornelissen,Ram Malladi,Rafael F. Duarte,Sebastian Giebel,Hildegard T. Greinix,Ernst Holler,Anita Lawitschka,Stephan Mielke,Mohamad Mohty,Mutlu Arat,Arnon Nagler,Jakob Passweg,Hélène Schoemans,Gérard Socié,Carlos Solano,Radovan Vrhovac,Robert Zeiser,Nicolaus Kröger,Grzegorz W. Basak +25 more
Reads0
Chats0
TLDR
Key updates to these recommendations include a broader use of rabbit anti-T-cell globulin; lower steroid doses for the management of grade 2 acute GVHD with isolated skin or upper gastrointestinal tract manifestations; fluticasone, azithromycin, and montelukast should be used for bronchiolitis obliterans syndrome; and the addition of newer treatment options for resteroid-refractory acute and chronic GV HD.About:
This article is published in The Lancet Haematology.The article was published on 2020-02-01. It has received 236 citations till now. The article focuses on the topics: Transplantation & Graft-versus-host disease.read more
Citations
More filters
Journal ArticleDOI
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Robert Zeiser,Nikolas von Bubnoff,Jason Butler,Mohamad Mohty,Dietger Niederwieser,Reuven Or,Jeff Szer,Eva Maria Wagner,Tsila Zuckerman,Bruyère Mahuzier,Judith Xu,Celine Wilke,Kunal K. Gandhi,Gérard Socié +13 more
TL;DR: Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than that observed with control therapy.
Journal ArticleDOI
How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT.
Olaf Penack,Christophe Peczynski,Mohamad Mohty,Ibrahim Yakoub-Agha,Jan Styczyński,Silvia Montoto,Rafael F. Duarte,Nicolaus Kröger,Hélène Schoemans,Christian Koenecke,Zinaida Peric,Grzegorz W. Basak +11 more
TL;DR: Transplantation-related mortality has decreased significantly in the past 40 years, and favorable data facilitate evidence-based treatment decisions on transplantation indications in the context of the availability of novel immunotherapies.
Journal ArticleDOI
Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Haris Ali,Dat Ngo,Ahmed Aribi,Shukaib Arslan,Sanjeet Dadwal,Guido Marcucci,Ryotaro Nakamura,Stephen J. Forman,Jason Chen,Monzr M. Al Malki +9 more
TL;DR: The safety and efficacy of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) emergency-use authorized (EUA) vaccines have been confirmed in the general population as discussed by the authors, but there are no data on its safety and tolerability or efficacy in recipients of allogeneic hematopoietic stem cell transplant (HCT).
Journal ArticleDOI
New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.
Nathaniel Edward Bennett Saidu,Chiara Bonini,Anne M. Dickinson,Magdalena Grce,Marit Inngjerdingen,Ulrike Koehl,Antoine Toubert,Robert Zeiser,Sara Galimberti +8 more
TL;DR: The current status and future directions of the use of these new drugs with particular spotlight on their targeting of specific intracellular signal transduction cascades important for cGvHD are presented, in order to shed some light on their possible mode of actions.
Journal ArticleDOI
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions
TL;DR: In this paper, the combination of calcineurin inhibitor (CNI) plus mycophenolate mophetil (MMF) was compared to CNI plus methotrexate.
References
More filters
Journal ArticleDOI
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report
Madan Jagasia,Hildegard T. Greinix,Mukta Arora,Kirsten M. Williams,Daniel Wolff,Edward W. Cowen,Jeanne Palmer,Daniel J. Weisdorf,Nathaniel S. Treister,Guang-Shing Cheng,Holly Kerr,Pamela Stratton,Rafael F. Duarte,George B. McDonald,Yoshihiro Inamoto,Afonso Celso Vigorito,Sally Arai,Manuel B. Datiles,David A. Jacobsohn,Theo Heller,Carrie L. Kitko,Sandra A. Mitchell,Paul J. Martin,Howard M. Shulman,Roy S. Wu,Corey Cutler,Georgia B. Vogelsang,Stephanie J. Lee,Steven Z. Pavletic,Mary E.D. Flowers +29 more
TL;DR: The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence, and focuses attention on the causes of organ-specific abnormalities to chronic GVHD.
Journal ArticleDOI
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
Rainer Storb,H. Joachim Deeg,John Whitehead,Frederick R. Appelbaum,Patrick G. Beatty,William I. Bensinger,C. Dean Buckner,Reginald A. Clift,Kristine Doney,Vernon T. Farewell,J. D. Hansen,Roger Hill,Lawrence G. Lum,Paul J. Martin,Robert W. McGuffin,Jean E. Sanders,Patricia S. Stewart,Keith M. Sullivan,Robert P. Witherspoon,Gary Yee,E. Donnall Thomas +20 more
TL;DR: It is concluded that the combination of methotrexate and cyclosporine is superior to cyclOSporine alone in the prevention of acute graft versus host disease after marrow transplantation for leukemia, and that this therapy may have a beneficial effect on long-term survival.
Journal ArticleDOI
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
Peter A. McSweeney,Peter A. McSweeney,Peter A. McSweeney,Dietger Niederwieser,Dietger Niederwieser,Dietger Niederwieser,Judith A. Shizuru,Judith A. Shizuru,Judith A. Shizuru,Brenda M. Sandmaier,Brenda M. Sandmaier,Brenda M. Sandmaier,Arthur J. Molina,Arthur J. Molina,Arthur J. Molina,David G. Maloney,David G. Maloney,David G. Maloney,Thomas R. Chauncey,Thomas R. Chauncey,Thomas R. Chauncey,Ted Gooley,Ted Gooley,Ted Gooley,U Hegenbart,U Hegenbart,U Hegenbart,Richard A. Nash,Richard A. Nash,Richard A. Nash,Jerald P. Radich,Jerald P. Radich,Jerald P. Radich,John L. Wagner,John L. Wagner,John L. Wagner,Steven Minor,Steven Minor,Steven Minor,Frederick R. Appelbaum,Frederick R. Appelbaum,Frederick R. Appelbaum,William I. Bensinger,William I. Bensinger,William I. Bensinger,Eileen Bryant,Eileen Bryant,Eileen Bryant,Mary E.D. Flowers,Mary E.D. Flowers,Mary E.D. Flowers,George E. Georges,George E. Georges,George E. Georges,F. Carl Grumet,F. Carl Grumet,F. Carl Grumet,Hans-Peter Kiem,Hans-Peter Kiem,Hans-Peter Kiem,Beverly Torok-Storb,Beverly Torok-Storb,Beverly Torok-Storb,Cong Yu,Cong Yu,Cong Yu,Karl G. Blume,Karl G. Blume,Karl G. Blume,Rainer Storb,Rainer Storb,Rainer Storb +71 more
TL;DR: A novel allografting approach, based on the use of postgrafting immunosuppression to control graft rejection and GVHD, has dramatically reduced the acute toxicities of allogRAFTing.
Journal ArticleDOI
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Jürgen Finke,Wolfgang Bethge,Claudia Schmoor,Hellmut Ottinger,Matthias Stelljes,Axel R. Zander,Liisa Volin,Tapani Ruutu,Dominik Heim,Rainer Schwerdtfeger,Karin Kolbe,Jiri Mayer,Johan Maertens,Werner Linkesch,Ernst Holler,Vladimir Koza,Martin Bornhäuser,Hermann Einsele,Hans-Jochem Kolb,Hartmut Bertz,Matthias Egger,Olga Grishina,Gérard Socié +22 more
TL;DR: The addition of ATG-F to GVHD prophylaxis with ciclosporin and methotrexate resulted in decreased incidence of acute and chronic GV HD without an increase in relapse or non-relapse mortality, and without compromising overall survival.
Journal ArticleDOI
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.
Richard A. Nash,Joseph H. Antin,Chatchada Karanes,Joseph W. Fay,Belinda R. Avalos,Andrew M. Yeager,Donna Przepiorka,Stella M. Davies,Finn Bo Petersen,Pamela Bartels,Donald N. Buell,William E. Fitzsimmons,Claudio Anasetti,Rainer Storb,Voravit Ratanatharathorn +14 more
TL;DR: The combination of tacrolimus and MTX after unrelated donor marrow transplantation significantly decreased the risk for acute GVHD than did the combination of CSP andMTX, with no significant increase in toxicity, infections, or leukemia relapse.
Related Papers (5)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report
Madan Jagasia,Hildegard T. Greinix,Mukta Arora,Kirsten M. Williams,Daniel Wolff,Edward W. Cowen,Jeanne Palmer,Daniel J. Weisdorf,Nathaniel S. Treister,Guang-Shing Cheng,Holly Kerr,Pamela Stratton,Rafael F. Duarte,George B. McDonald,Yoshihiro Inamoto,Afonso Celso Vigorito,Sally Arai,Manuel B. Datiles,David A. Jacobsohn,Theo Heller,Carrie L. Kitko,Sandra A. Mitchell,Paul J. Martin,Howard M. Shulman,Roy S. Wu,Corey Cutler,Georgia B. Vogelsang,Stephanie J. Lee,Steven Z. Pavletic,Mary E.D. Flowers +29 more
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease
Madan Jagasia,Hildegard T. Greinix,Mukta Arora,Kirsten M. Williams,Daniel Wolff,Edward W. Cowen,Jeanne Palmer,Daniel J. Weisdorf,Nathaniel S. Treister,Guang-Shing Cheng,Holly Kerr,Pamela Stratton,Rafael F. Duarte,George B. McDonald,Yoshihiro Inamoto,Afonso Celso Vigorito,Sally Arai,Manuel B. Datiles,David A. Jacobsohn,Theo Heller,Carrie L. Kitko,Sandra A. Mitchell,Paul J. Martin,Howard M. Shulman,Roy S. Wu,Corey Cutler,Georgia B. Vogelsang,Stephanie J. Lee,Steven Z. Pavletic,Mary E.D. Flowers +29 more
Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy
Robert Zeiser,Bruce R. Blazar +1 more